Journal News

Do ribosomal traffic jams cause Huntington’s disease?

Uzma Rentia
By Uzma Rentia
Sept. 5, 2024

Huntington's disease, or HD, a genetic disorder that affects about one in every 10,000 people in the U.S., is inherited in an autosomally dominant manner, meaning that a person with the condition has a 50% chance of passing it on to their child. HD kills important neurons in the brain, causing uncontrollable movements and cognitive and psychiatric changes.

While scientists have long known that HD is caused by a cytosine–adenine–guanine trinucleotide repeat in the Huntingtin gene contained on chromosome 4, they are still studying the biological mechanisms that guide the disease process. In particular, researchers have implicated mitochondrial dysfunction in the pathophysiology of HD, and it is an ongoing focus of study.

Investigators at the Wertheim University of Florida Scripps Research Institute recently used novel techniques to examine mRNA translation within the mitochondria of mice genetically altered to have HD. They found that ribosomes — particles responsible for creating proteins from instructions encoded in mRNA — get clustered and jammed on mitochondrial mRNA transcripts. The team published these new findings, in the journal Molecular & Cellular Proteomics.

Srinivasa Subramaniam, an associate professor at Wertheim UF Scripps, was the lead author on the study. “Imagine going from Baltimore to Washington, D.C., and there are too many cars, and they are all jammed up,” he said. “Just because there are many cars does not mean they are all reaching their destination.

“So, what does that mean for the patient? That means that the patient may have difficulty translating their mitochondrial protein. And that may lead to problems in the assembly of these complexes, which may lead to problems in mitochondrial function.”

Mitochondrial protein synthesis is diminished in Huntington’s disease cells. These mouse striatal cells have a normal genotype (left) or are heterozygous (center) or homozygous (right) for a Huntington’s disease mutation. Puromycin uptake is shown in green and represents the cellular protein translation rate. Nuclei are shown in blue.
MCP
Mitochondrial protein synthesis is diminished in Huntington’s disease cells. These mouse striatal cells have a normal genotype (left) or are heterozygous (center) or homozygous (right) for a Huntington’s disease mutation. Puromycin uptake is shown in green and represents the cellular protein translation rate. Nuclei are shown in blue.

This project followed from Subramaniam’s previous work, which demonstrated high expression of fragile X messenger ribonucleoprotein, or FMRP, a protein that blocks ribosomes in HD. Consequently, he was curious to see the spatial distribution of ribosomes on mitochondrial mRNA, so Subramaniam turned to a technique called Ribo-Seq, which provides a snapshot of the location and density of ribosomes on a given mRNA transcript. He had no experience with the technique and immediately faced challenges.

“I am a biochemist by training,” Subramaniam said. “So I needed to sit and write hundreds of emails like ‘Can you help me?’ all over the world.”

He connected with collaborators in France and Ireland and took on a postdoc with Ribo-Seq experience. Almost four years later, Subramaniam and his lab published the results of their work. And with these results come new questions.

Previous research has shown that deleting the FMRP protein can prevent some cognitive deficits observed in HD. Subramaniam wants to investigate how modulating the expression of FMRP can affect the spatial distribution of ribosomes on mRNA transcripts. He also wants to see how communication between the cytoplasm and mitochondria contributes to what he likens to a "traffic jam."   He hypothesizes that the cytoplasm inhibits proper functioning of mitochondrial mRNA, creating confusion.

“Imagine if you are traveling through a tunnel, and you close that tunnel,” he said. “Who puts on that brake? Who triggered that pathway? What is the signal that makes this traffic jam? That is what I want to know in more detail at the molecular level.”

He hopes this work has practical applications as well.

“How can we use small-molecule screening to reverse this phenotype?” he said. “My goal is to identify the mechanisms and then leverage potential therapeutics.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Uzma Rentia
Uzma Rentia

Uzma Rentia is a third-year medical student at George Washington University in Washington, D.C., who is also enrolled in the University of California, San Diego Science Writing Certificate Program. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Redefining lipid biology from droplets to ferroptosis
Award

Redefining lipid biology from droplets to ferroptosis

Feb. 5, 2026

James Olzmann will receive the ASBMB Avanti Award in Lipids at the ASBMB Annual Meeting, March 7–10, just outside of Washington, D.C.

Women’s health cannot leave rare diseases behind
Essay

Women’s health cannot leave rare diseases behind

Feb. 4, 2026

A physician living with lymphangioleiomyomatosis and a basic scientist explain why patient-driven, trial-ready research is essential to turning momentum into meaningful progress.

Life in four dimensions: When biology outpaces the brain
Profile

Life in four dimensions: When biology outpaces the brain

Jan. 27, 2026

Nobel laureate Eric Betzig will discuss his research on information transfer in biology from proteins to organisms at the 2026 ASBMB Annual Meeting.

Fasting, fat and the molecular switches that keep us alive
Interview

Fasting, fat and the molecular switches that keep us alive

Jan. 27, 2026

Nutritional biochemist and JLR AE Sander Kersten has spent decades uncovering how the body adapts to fasting. His discoveries on lipid metabolism and gene regulation reveal how our ancient survival mechanisms may hold keys to modern metabolic health.

Redefining excellence to drive equity and innovation
Award

Redefining excellence to drive equity and innovation

Jan. 22, 2026

Donita Brady will receive the ASBMB Ruth Kirschstein Award for Maximizing Access in Science at the ASBMB Annual Meeting, March 7–10, just outside of Washington, D.C.

Mining microbes for rare earth solutions
Award

Mining microbes for rare earth solutions

Jan. 14, 2026

Joseph Cotruvo, Jr., will receive the ASBMB Mildred Cohn Young Investigator Award at the ASBMB Annual Meeting, March 7–10, just outside of Washington, D.C.